Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2)

Aim: Talimogene laherparepvec (T-VEC) is an intralesional therapy for unresectable, metastatic melanoma. T-VEC real-world use in the context of anti-PD1-based therapy requires further characterization. Materials & methods: A retrospective review of T-VEC use from 1 January 2017 and 31 March 2018...

Full description

Bibliographic Details

Published in:	Melanoma Management
Main Authors:	James Sun, Brian R Gastman, Lucy McCahon, Elizabeth I Buchbinder, Igor Puzanov, Michele Nanni, James M Lewis, Richard D Carvajal, Shahnaz Singh-Kandah, Anupam M Desai, Leon Raskin, Carrie M Nielson, Rubina Ismail, Jonathan S Zager
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2020-07-01
Subjects:	combination therapy immunotherapy metastatic melanoma oncolytic virus real-world evidence talimogene laherparepvec
Online Access:	https://www.futuremedicine.com/doi/10.2217/mmt-2020-0005